<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157889">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659593</url>
  </required_header>
  <id_info>
    <org_study_id>PROCOG-SEP</org_study_id>
    <nct_id>NCT01659593</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients</brief_title>
  <acronym>PROCOG-SEP</acronym>
  <official_title>Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients. A Double Blind Randomized Multicenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive disorders are well-known in multiple sclerosis (MS), even in earlier stages of the
      disease. They effect personal life. Their management may be overlooked. The evidence-based
      program proposes exercises to both stimulate preserved functions and develop new abilities
      compensating for cognitive disabilities.

      Aim of the study is to evaluate the efficiency of the remedial program (PROCOG-SEP) designed
      for MS patients, compared to an interactive discussion program(DISINT) 140 multiple
      sclerosis patients will be randomly assigned in one the program for 13 sessions over a
      6-month period.

      Main outcome criteria is evolution of SRT-LIST before and after program.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>cognitive function measured by SRT-List score</measure>
    <time_frame>0-9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life measured by MusiQol</measure>
    <time_frame>0 -9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>cognitive function: verbal memory (SRT), visuospatial memory (10/36), verbal fluency (animal categories),empans, code ,DO80, cognitive complaint</measure>
    <time_frame>0-9 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cognitive Disorders</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>procog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cognitive remedial program 13 sessions over a 6-month period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DISINT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interactive discussion program of 13 group sessions in a 6-month period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>procog</intervention_name>
    <description>3 to 5 people group program</description>
    <arm_group_label>procog</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>DISINT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 ≤Aged ≤ 50 at baseline

          -  Must be able to understand and read french language

          -  Must sign the informed consent form

          -  Must be affiliate to French social security

          -  multiple sclerosis confirmed by Mac Donald criteria

          -  EDSS ≤ 5.0 at baseline

          -  Duration of multiple sclerosis ≤ 20 years at baseline

          -  mild cognitive disorder ( at least 2 cognitive tasks, at most 5 )

        Exclusion Criteria:

          -  under legal protection

          -  treatment by corticosteroids in the past 4 weeks

          -  cognitive remedial program already done

          -  neuropsychologic assessment in the past 3 months

          -  having an other chronic disease

          -  having an other neurologic disease

          -  alcohol or drug addiction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University hospital Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc Debouverie, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 30, 2012</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive disorders</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>neuropsychology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
